Relationship between quality of life (QoL) and clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients after chemotherapy: Results from the AFFIRM study.

被引：1
|
作者：
Miller, Kurt
Cella, David
De Phung
Naidoo, Shevani
Holmstrom, Stefan
Ivanescu, Cristina
Skaltsa, Konstantina
机构：
[1] Charite, Dept Urol, Berlin, Germany
[2] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[3] Astellas Pharma Europe, Leiden, Netherlands
[4] Astellas Pharma, Chertsey, England
[5] Quintiles, Hoofddorp, Netherlands
[6] Quintiles, Barcelona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.5060
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5060
引用
收藏
页数：3
相关论文
共 50 条
  • [21] IS THERE A RELATIONSHIP BETWEEN PATIENT-REPORTED OUTCOMES (PROS) AND CLINICAL OUTCOMES IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) POST-DOCETAXEL?
    Traina, S.
    Li, T.
    Johnson, K.
    Ho, K. F.
    Molina, A.
    Cella, D.
    VALUE IN HEALTH, 2015, 18 (07) : A470 - A470
  • [22] Treatment sequence in elderly metastatic castration-resistant prostate cancer (mCRPC) patients (pts) in a prospective cohort study.
    Jose Mendez-Vidal, Maria
    Lozano, Rebeca
    Castro, Elena
    Romero-Laorden, Nuria
    Rodriguez-Vida, Alejo
    Lainez, Nuria
    Hernandez, Amaia
    Villatoro, Rosa
    Zambrana, Francisco
    Villa Guzman, Jose Carlos
    Garcia Dominguez, Rocio
    Galvan Ruiz, Saray
    Escribano, Ricardo
    Gallardo Diaz, Enrique
    Querol, Rosa
    Luque, Raquel
    Gonzalez del Alba, Aranzazu
    Puente, Javier
    Olmos, David
    Lorente, David
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [23] QUALITY OF LIFE OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: RESULTS FROM AN OBSERVATIONAL STUDY IN 6 EUROPEAN COUNTRIES
    Dass, R. N.
    Hamberg, P.
    Spencer, M.
    Price, P. Wheatley
    ANNALS OF ONCOLOGY, 2012, 23 : 314 - 314
  • [24] Effect of enzalutamide on health-related quality of life (HRQoL) in men with metastatic castration-resistant prostate cancer (mCRPC) following docetaxel-based therapy: Results from the AFFIRM study
    Miller, Kurt
    Scher, Howard I.
    Fizazi, Karim
    Basch, Ethan M.
    Sternberg, Cora N.
    Hirmand, Mohammad
    Cella, David
    Ivanescu, Cristina
    Phung, De
    Spalding, James Robert
    Bui, Cat N.
    Holmstrom, Stefan
    De Bono, Johann Sebastian
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [25] Quality of life outcomes for patients with metastatic castration-resistant prostate cancer and pretreatment prognostic score
    Oyenuga, Mosunmoluwa
    Halabi, Susan
    Oyenuga, Abayomi
    McSweeney, Sean
    Morgans, Alicia K.
    Ryan, Charles J.
    Prizment, Anna
    PROSTATE, 2023, 83 (07): : 688 - 694
  • [26] The association between health-related quality-of-life scores and clinical outcomes in metastatic castration-resistant prostate cancer patients: Exploratory analyses of AFFIRM and PREVAIL studies
    Beer, Tomasz M.
    Miller, Kurt
    Tombal, Bertrand
    Cella, David
    Phung, De
    Holmstrom, Stefan
    Ivanescu, Cristina
    Skaltsa, Konstantina
    Naidoo, Shevani
    EUROPEAN JOURNAL OF CANCER, 2017, 87 : 21 - 29
  • [27] Abiraterone acetate (AA) in patients with metastatic castration-resistant prostate cancer (mCRPC) and prior therapy with ketoconazole: A Prostate Cancer Clinical Trials Consortium study.
    Ryan, C. J.
    Harzstark, A. L.
    Lin, A. M.
    Fong, L.
    Grycz, K.
    Szmulewitz, R. Z.
    Weinberg, V. K.
    Molina, A.
    Small, E. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [28] QoLiTime: Quality-of-Life (QoL) analysis of patients with metastatic castration resistant prostate cancer (mCRPC) treated with cabazitaxel in daily clinical practice
    Hofheinz, R. D.
    Al-Batran, S. E.
    Windemuth-Kieselbach, C.
    Hammerer, P.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S499 - S499
  • [29] Association of alkaline phosphatase with clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): results from COU-AA-302
    Mainwaring, P.
    Yu, E. Y.
    Londhe, A.
    Van Poppel, H.
    Rathkopf, D. E.
    Smith, M. R.
    Souza, P.
    Griffin, T. W.
    Ryan, C. J.
    BJU INTERNATIONAL, 2014, 113 : 21 - 21
  • [30] Cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC): Real-life use, effectiveness, safety, and quality of life (QoL) in the FUJI cohort.
    Oudard, Stephane
    Fizazi, Karim
    Joly, Florence
    Tubach, Florence
    Rouyer, Magali
    Lamarque, Stephanie
    Guiard, Estelle
    Balestra, Aurelie
    Lacueille, Clementine
    Jove, Jeremy
    Droz-Perroteau, Cecile
    Fourrier-Reglat, Annie
    Moore, Nicholas
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345